Ounchanum P.Achalapong J.Teeraananchai S.Gatechompol S.Phongsamart W.Chokephaibulkit K.Tran D.N.H.Dang H.L.D.Teeratakulpisarn N.Chalermchockcharoenkit A.Singtoroj T.Sohn A.H.Phanuphak N.Mahidol University2024-03-142024-03-142023-11-16Sexual Health Vol.21 No.1 (2023)14485028https://repository.li.mahidol.ac.th/handle/20.500.14594/97578Background. Females with perinatal HIV (PHIV) infection are at elevated risk for anogenital high-risk human papillomavirus (HR-HPV) infection. Limited data are available around the effect of the HPV vaccination after initiation of sexual activity among PHIV youth. This study aims to assess the impact of a bivalent HPV vaccination on the persistence of anogenital HR-HPV among sexually active female PHIV youth and matched HIV-negative controls aged 12–24 years in Thailand and Vietnam. Methods. During a 3-year study, prevalent, incident, and persistent HR-HPV infection were assessed at annual visits. A subset of participants received a bivalent HPV vaccine. Samples were taken for HPV testing from the vagina, cervix, and anus. HR-HPV persistence was defined as the detection of the same genotype(s) at any anogenital compartment over ≥ two consecutive visits. Results. Of the 93 PHIV and 99 HIV-negative female youth enrolled in this study, 25 (27%) PHIV and 22 (22%) HIV-negative youth received a HPV vaccine. Persistent infection with any HR-HPV type was significantly lower among PHIV youth who received the vaccine compared to those who did not (33% vs 61%, P = 0.02); a difference was not observed among HIV-negative youth (35% vs 50%, P = 0.82). PHIV infection (adjusted prevalence ratio [aPR] 2.31, 95% CI 1.45–3.67) and not receiving a HPV vaccine (aPR, 1.19, 95%CI 1.06–1.33) were associated with persistent anogenital HR-HPV infection. Conclusions. Bivalent HPV vaccination after initiation of sexual activity was associated with reduced persistence of anogenital HR-HPV infection in Southeast Asian PHIV female youth, which may be related to vaccine cross-protection. Primary and catch-up HPV vaccinations should be prioritised for children and youth with HIV.MedicineArticleSCOPUS10.1071/SH221852-s2.0-851846659391449898737967583